Literature DB >> 19997836

[How to use PSA in 2009].

Anton Ponholzer1, Franz Stoiber, Wolfgang Loidl, Michael Rauchenwald, Paul Schramek, Stephan Madersbacher.   

Abstract

PSA is without any doubt the most frequently used marker in urology due to its helpful information regarding various aspects of diagnosis, therapy and prognosis in men with prostate cancer. On the other hand, many controversies still exist about the various indications for PSA-determination. The following overview is aimed to analyse the current status of PSA in the management of men undergoing screening, therapy or follow-up of prostate cancer. Anyhow, a detailed knowledge of how to use and interpret PSA and PSA-kinetics is considered to play a crucial role in prostate cancer patients. Current strategies are aimed to start and stop PSA-use earlier.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19997836     DOI： 10.1007/s10354-009-0718-0

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  23 in total

Review 1.  [EAU guidelines on prostate cancer].

Authors:  Axel Heidenreich; Gunna Aus; Michel Bolla; Steven Joniau; Vsevolod B Matveev; Hans Peter Schmid; Filliberto Zattoni
Journal:  Actas Urol Esp       Date:  2009-02       Impact factor: 0.994

2.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

3.  The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy.

Authors:  Stephen J Freedland; Leslie A Mangold; Patrick C Walsh; Alan W Partin
Journal:  J Urol       Date:  2005-10       Impact factor: 7.450

4.  Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.

Authors:  Alexandra J Stewart; Howard I Scher; Ming-Hui Chen; David G McLeod; Peter R Carroll; Judd W Moul; Anthony V D'Amico
Journal:  J Clin Oncol       Date:  2005-09-20       Impact factor: 44.544

5.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.

Authors:  A W Partin; L A Mangold; D M Lamm; P C Walsh; J I Epstein; J D Pearson
Journal:  Urology       Date:  2001-12       Impact factor: 2.649

6.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

Authors:  W J Catalona; D S Smith; D K Ornstein
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

7.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

8.  Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors.

Authors:  Ming Yin; Sheldon Bastacky; Uma Chandran; Michael J Becich; Rajiv Dhir
Journal:  J Urol       Date:  2008-01-22       Impact factor: 7.450

9.  Pathological characteristics of prostate cancer detected through prostate specific antigen based screening.

Authors:  Stacy Loeb; Chris M Gonzalez; Kimberly A Roehl; Misop Han; Jo Ann V Antenor; Ronald L Yap; William J Catalona
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

Review 10.  [PSA--Quo vadis?].

Authors:  C Börgermann; H Loertzer; H-J Luboldt; P Hammerer; P Fornara; M Graefen; H Rübben
Journal:  Urologe A       Date:  2009-09       Impact factor: 0.639
View more
  1 in total

1.  Prostate-specific antigen: its relationship with alcohol intake and tobacco.

Authors:  Jorge D Escandriolo Nackauzi; Raúl H Colla; Graciela R Ravazzani; María I Gaido; Patricia Bertolotto; Adriana B Actis
Journal:  Med Oncol       Date:  2011-04-12       Impact factor: 3.064
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.